On March 30, 2017 Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, reported that Curis scientists will present data from its IRAK4 kinase inhibitor development candidate, CA-4948, at the Annual Meeting of American Association of Cancer Research (AACR) (Free AACR Whitepaper) to be held April 1 — 5, 2017 in Washington, D.C (Press release, Curis, MAR 30, 2017, View Source [SID1234518321]). Curis has exclusive license to CA-4948 under a collaboration agreement with Aurigene established in 2015. Schedule your 30 min Free 1stOncology Demo! Additional information follows. Abstracts can be accessed at www.aacr.org.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation
Date/Time: Monday, Apr. 3, 2017, 8:00 AM – 12:00 PM
Session Title: Novel Molecular Targets 1
Session Category: Experimental and Molecular Therapeutics
Presentation Title: Efficacy of the IRAK4 Inhibitor CA-4948 in Patient-Derived Xenograft Models of
Diffuse Large B Cell Lymphoma
Abstract Number: 1168